GenMark Diagnostics (GNMK) PT Lowered to $9 at Canaccord Genuity, Following Announcement of CEO Transition
Tweet Send to a Friend
Canaccord Genuity analyst Max Masucci lowered the price target on GenMark Diagnostics (NASDAQ: GNMK) to $9.00 (from $11.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
